• S&P 500: 1,342.64
  • Change: -0.69%
$4.05 -0.10 (-2.41%)
2/10/2012 4:00 PM

Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Current Price $4.05 Mkt Cap $499.84M
Open $4.15 P/E Ratio 0.00
Prev. Close $4.15 Div. (Yield) N/A (N/A)
Daily Range $3.94 - $4.19 Volume 1,809,001
52-Wk Range $1.75 - $4.48 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think DVAX will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

131 Outperform
8 Underperform
 

All-Star Players

22 Outperform
3 Underperform
 

Wall Street

6 Outperform
0 Underperform
 

Top DVAX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

foolphighter (< 20)
Submitted January 12, 2007

Small biotech has recently released promising late stage trial results for its HEPLSAV hepatitus B vaccine drug, as well as encouraging earlier stage results for its TLR9 agonist in cancer indications. The stock took a large hit Jan. 8th when its… More

Add Comment | Reply | Report this Post

zzlangerhans (99.27)
Submitted December 21, 2011

I recently did well on a green thumb on Dynavax, with the justification I provided here: http://caps.fool.com/Pitch/DVAX/5983252/dynavax-rose-as-high-as-316-in.aspxI think the momentum has run out for Dynavax, and there's a good chance the share… More

Add Comment | Reply | Report this Post
DVAX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about DVAX.

Recs

0
Member Avatar helpmesav (< 20) Submitted: 12/31/2011 12:32:50 PM : Outperform Start Price: $3.37 DVAX Score: +15.01

Heplisav will be approved last quarter 2012 and their pipleine is strong

Report this Post Add Comment | Reply | Permalink

Recs

1
Member Avatar zzlangerhans (99.27) Submitted: 12/21/2011 11:58:27 AM : Underperform Start Price: $3.28 DVAX Score: -14.70

I recently did well on a green thumb on Dynavax, with the justification I provided here: http://caps.fool.com/Pitch/DVAX/5983252/dynavax-rose-as-high-as-316-in.aspx

I think the momentum has run out for Dynavax, and there's a good chance the share price will drop substantially between now and when any regulatory decisions are made regarding Heplisav.

1. The Heplisav ship has been listing heavily ever since the FDA shot down the vaccine for general use, supposedly due to a single instance of autoimmune disease in a recipient. Merck dumped the partnership. The company is now seeking approval of Heplisav in a relatively small subset of the general population (over 40 and chronic kidney disease).

2. There were three serious autoimmune events reported in the follow-up phase III trial.

3. The Heplisav BLA submission was postponed from Q4 2011 to Q1 2012 without much explanation.

4. The company has taken advantage of the stock run-up by raising money heavily through dilutive financing. Prudent, yes. Optimistic, no. The cash cushion may make Dynavax another green thumb stock if the share price gets beaten up badly on Heplisav rejection or sell-off after approval.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar Bumkinpops (< 20) Submitted: 9/21/2011 7:30:43 PM : Outperform Start Price: $1.96 DVAX Score: +88.39

Lead product Heplisav should be approved as efficacy, safety and manufacturing consistency all appear to have been achieved. FDA submition within 3 months and significant advantages over current market leader engerixB. This product alone justifies three times the current market cap. Add to that the pipeline, most significanlty the Universal flu vaccine, based on the same technology that created Heplisav.

Report this Post Add Comment | Reply | Permalink
View All 28 Pitches »

Leaderboard

Find the members with the highest scoring picks in DVAX.

Score Leader

dnovotny8

dnovotny8 (< 20) Score: +126.60

The Score Leader is the player with the highest score across all their picks in DVAX.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
dnovotny8 < 20 9/16/2010 Outperform 5Y $1.65 +145.47% +18.87% +126.60 0 Comment
davemarriner < 20 8/31/2010 Outperform 1Y $1.63 +148.47% +27.68% +120.79 1 Comment
fishmouse < 20 5/6/2010 Outperform 1Y $1.74 +132.76% +15.57% +117.19 1 Comment
dipin4u 59.96 5/6/2010 Outperform 5Y $1.74 +132.76% +15.57% +117.19 0 Comment
jharrold09 49.83 9/27/2010 Outperform 3Y $1.80 +125.00% +16.98% +108.02 0 Comment
tholewczynski 33.31 8/27/2010 Outperform 5Y $1.75 +131.43% +28.05% +103.38 0 Comment
Biotoday 32.75 10/7/2010 10/4/2011 Outperform 3M $1.86 +117.74% +15.99% +101.75 1 Comment
adambeef < 20 8/20/2010 Outperform 5Y $1.80 +125.00% +24.92% +100.08 0 Comment
hayrettin 69.43 10/6/2011 Outperform 5Y $1.89 +114.29% +17.49% +96.80 0 Comment
Snowpro1 < 20 8/18/2010 Outperform 3W $1.85 +118.92% +22.66% +96.26 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackMLVCo 47.66 1/4/2012 Outperform NS $3.27 +23.85% +5.63% +18.22 0 Comment
TrackZacks 71.09 12/27/2010 Outperform 3M $3.04 +33.22% +6.93% +26.29 1 Comment
TrackJefferies 84.73 11/8/2010 Outperform NS $2.14 +89.25% +9.83% +79.43 0 Comment
TrackWedbush 84.95 5/13/2010 Outperform NS $2.04 +98.53% +14.71% +83.82 0 Comment
TrackSusquehanna 78.11 9/10/2009 Outperform NS $2.95 +37.29% +30.06% +7.23 0 Comment
TrackZacks 71.09 2/20/2008 Outperform 3M $4.95 -55.56% -4.12% -51.44 3/19/2008 @ $2.20 1 Comment
TrackCreditSuiss 92.69 10/3/2007 Outperform NS $4.50 -10.00% -8.48% -1.52 0 Comment
trackmerriman 70.89 12/20/2006 Outperform NS $9.26 -73.00% -8.10% -64.90 3/18/2008 @ $2.50 0 Comment
TrackJMP 84.95 11/30/2006 Outperform NS $9.90 -46.67% +3.87% -50.53 2/26/2007 @ $5.28 0 Comment

Featured Broker Partners